Header Logo

Connection

Paul Hesketh to Neoplasms

Back to Details
This is a "connection" page, showing publications Paul Hesketh has written about Neoplasms.
Paul Hesketh
Connection Strength
2.035
Neoplasms
  1. Hesketh PJ, Bohlke K, Kris MG. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update Summary. J Oncol Pract. 2017 12; 13(12):825-830.
    View in: PubMed
    Score: 0.279
  2. Hesketh PJ, Schnadig ID, Schwartzberg LS, Modiano MR, Jordan K, Arora S, Powers D, Aapro M. Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy. Cancer. 2016 Aug 01; 122(15):2418-25.
    View in: PubMed
    Score: 0.255
  3. Jordan K, Warr DG, Hinke A, Sun L, Hesketh PJ. Defining the efficacy of neurokinin-1 receptor antagonists in controlling chemotherapy-induced nausea and vomiting in different emetogenic settings-a meta-analysis. Support Care Cancer. 2016 May; 24(5):1941-1954.
    View in: PubMed
    Score: 0.246
  4. Grunberg SM, Herrstedt J, Hesketh PJ. Birth and re-birth. Support Care Cancer. 2008 Sep; 16(9):979.
    View in: PubMed
    Score: 0.150
  5. Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group. J Clin Oncol. 2003 Nov 15; 21(22):4112-9.
    View in: PubMed
    Score: 0.107
  6. Hesketh PJ, Crews JR, Cohen R, Blackburn LM, Friedman CJ. Antiemetic efficacy of single-dose oral granisetron (1 mg vs 2 mg) with moderately emetogenic chemotherapy. Cancer J. 2000 May-Jun; 6(3):157-61.
    View in: PubMed
    Score: 0.084
  7. Hesketh PJ, Roman A, Hesketh AM, Perez EA, Edelman M, Gandara DR. Control of high-dose-cisplatin-induced emesis with an all-oral three-drug antiemetic regimen. Support Care Cancer. 2000 Jan; 8(1):46-8.
    View in: PubMed
    Score: 0.082
  8. Hesketh PJ, Gralla RJ, du Bois A, Tonato M. Methodology of antiemetic trials: response assessment, evaluation of new agents and definition of chemotherapy emetogenicity. Support Care Cancer. 1998 May; 6(3):221-7.
    View in: PubMed
    Score: 0.073
  9. Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, Dusetzina SB, Eng C, Feyer PC, Jordan K, Noonan K, Sparacio D, Somerfield MR, Lyman GH. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2017 Oct 01; 35(28):3240-3261.
    View in: PubMed
    Score: 0.069
  10. Hesketh P, Navari R, Grote T, Gralla R, Hainsworth J, Kris M, Anthony L, Khojasteh A, Tapazoglou E, Benedict C, Hahne W. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group. J Clin Oncol. 1996 Aug; 14(8):2242-9.
    View in: PubMed
    Score: 0.065
  11. Aapro M, Hesketh PJ, Jordan K, Gralla RJ, Rossi G, Rizzi G, Palmas M. Safety of an Oral Fixed Combination of Netupitant and Palonosetron (NEPA): Pooled Data From the Phase II/III Clinical Program. Oncologist. 2016 Apr; 21(4):494-502.
    View in: PubMed
    Score: 0.063
  12. Hesketh PJ, Gandara DR, Hesketh AM, Facada A, Perez EA, Webber LM, Martin LA, Cramer MB, Hahne WF. Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide. Support Care Cancer. 1996 Mar; 4(2):141-6.
    View in: PubMed
    Score: 0.063
  13. Hesketh PJ. Treatment of chemotherapy-induced emesis in the 1990s: impact of the 5-HT3 receptor antagonists. Support Care Cancer. 1994 Sep; 2(5):286-92.
    View in: PubMed
    Score: 0.057
  14. Hesketh PJ, Warr DG, Street JC, Carides AD. Differential time course of action of 5-HT3 and NK1 receptor antagonists when used with highly and moderately emetogenic chemotherapy (HEC and MEC). Support Care Cancer. 2011 Sep; 19(9):1297-302.
    View in: PubMed
    Score: 0.043
  15. Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med. 2008 Jun 05; 358(23):2482-94.
    View in: PubMed
    Score: 0.037
  16. Hesketh PJ. Palliative care in the cancer patient. J Am Geriatr Soc. 1987 Sep; 35(9):883-5.
    View in: PubMed
    Score: 0.035
  17. Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM, Morrow GR, Chinnery LW, Chesney MJ, Gralla RJ, Grunberg SM. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol. 2006 Jun 20; 24(18):2932-47.
    View in: PubMed
    Score: 0.032
  18. Herrstedt J, Muss HB, Warr DG, Hesketh PJ, Eisenberg PD, Raftopoulos H, Grunberg SM, Gabriel M, Rodgers A, Hustad CM, Horgan KJ, Skobieranda F. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer. 2005 Oct 01; 104(7):1548-55.
    View in: PubMed
    Score: 0.031
  19. Oo TH, Hesketh PJ. Drug insight: New antiemetics in the management of chemotherapy-induced nausea and vomiting. Nat Clin Pract Oncol. 2005 Apr; 2(4):196-201.
    View in: PubMed
    Score: 0.030
  20. Hesketh PJ. New treatment options for chemotherapy-induced nausea and vomiting. Support Care Cancer. 2004 Aug; 12(8):550-4.
    View in: PubMed
    Score: 0.028
  21. Hesketh PJ, Batchelor D, Golant M, Lyman GH, Rhodes N, Yardley D. Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches. Support Care Cancer. 2004 Aug; 12(8):543-9.
    View in: PubMed
    Score: 0.028
  22. Hesketh PJ, Arena F, Patel D, Austin M, D'Avirro P, Rossi G, Colowick A, Schwartzberg L, Bertoli LF, Cole JT, Demetri G, Dessypris E, Dobbs T, Eisenberg P, Fleischman R, Hall J, Hoffman PC, Laber DA, Leonard J, Lester EP, McCachren S, McMeekin S, Meza L, Miller DS, Nand S, Oliff I, Paroly W, Pawl L, Perez A, Raftopoulos H, Rigas J, Rowland K, Scullin DC, Tezcan H, Waples J, Ward J, Yee LK. A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies. Cancer. 2004 Feb 15; 100(4):859-68.
    View in: PubMed
    Score: 0.027
  23. Chawla SP, Grunberg SM, Gralla RJ, Hesketh PJ, Rittenberg C, Elmer ME, Schmidt C, Taylor A, Carides AD, Evans JK, Horgan KJ. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer. 2003 May 01; 97(9):2290-300.
    View in: PubMed
    Score: 0.026
  24. Hesketh PJ, Van Belle S, Aapro M, Tattersall FD, Naylor RJ, Hargreaves R, Carides AD, Evans JK, Horgan KJ. Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer. 2003 May; 39(8):1074-80.
    View in: PubMed
    Score: 0.026
  25. Hesketh PJ. Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. Oncologist. 1999; 4(3):191-6.
    View in: PubMed
    Score: 0.019
  26. Tavorath R, Hesketh PJ. Drug treatment of chemotherapy-induced delayed emesis. Drugs. 1996 Nov; 52(5):639-48.
    View in: PubMed
    Score: 0.016
  27. Hesketh PJ. Oral ondansetron: a useful addition to the supportive care armamentarium? Am J Clin Oncol. 1994 Apr; 17(2):147-9.
    View in: PubMed
    Score: 0.014
  28. Hesketh PJ, Harvey WH, Harker WG, Beck TM, Ryan T, Bricker LJ, Kish JA, Murphy WK, Hainsworth JD, Haley B. A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis. J Clin Oncol. 1994 Mar; 12(3):596-600.
    View in: PubMed
    Score: 0.014
  29. Hainsworth JD, Hesketh PJ. Single-dose ondansetron for the prevention of cisplatin-induced emesis: efficacy results. Semin Oncol. 1992 Dec; 19(6 Suppl 15):14-9.
    View in: PubMed
    Score: 0.013
  30. Roila F, Hesketh PJ, Herrstedt J. Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol. 2006 Jan; 17(1):20-8.
    View in: PubMed
    Score: 0.008
  31. Whitmore JB, Kris MG, Hesketh PJ, Grote TH, DuBois DM, Cramer MB, Hahne WF. Rationale for the use of a single fixed intravenous dolasetron dose for the prevention of cisplatin-induced nausea and vomiting. Pooled analysis of 14 clinical trials. Support Care Cancer. 1998 Sep; 6(5):473-8.
    View in: PubMed
    Score: 0.005
  32. Ballatori E, Roila F, De Angelis V, Ciccarese G, Palladino MA, Tonato M, Del Favero A, Herrstedt J, Dicato M, du Bois A, Hesketh P, Kris M, Gralla RJ. Clinical and methodological issues in antiemetic therapy: a worldwide survey of experts' opinions. Multinational Association of Supportive Care in Cancer. Support Care Cancer. 1997 Jul; 5(4):269-73.
    View in: PubMed
    Score: 0.004
  33. Burris H, Hesketh P, Cohn J, Moriconi W, Ryan T, Friedman C, Fitts D. Efficacy and safety of oral granisetron versus oral prochlorperazine in preventing nausea and emesis in patients receiving moderately emetogenic chemotherapy. Cancer J Sci Am. 1996 Mar-Apr; 2(2):85-90.
    View in: PubMed
    Score: 0.004
  34. Navari R, Gandara D, Hesketh P, Hall S, Mailliard J, Ritter H, Friedman C, Fitts D. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group. J Clin Oncol. 1995 May; 13(5):1242-8.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.